Factors associated with concurrent malignancy risk among patients with incidental solitary pulmonary nodule: A systematic review taskforce for developing rapid recommendations. Issue 2 (6th July 2022)

• Record Type: Journal Article
• Authors: Zhu, Yuqi; Yang, Lan; Li, Qianrui; Chen, Bojiang; Hao, Qiukui; Sun, Xin; Tan, Jing; Li, Weimin
• Is Part Of: Journal of evidence-based medicine. Volume 15:Issue 2(2022)
• Page Start: 106
• Page End: 122
• Publication Date: 2022-07-06
• Subjects: concurrent malignancy risk -- lung cancer -- meta‐analysis -- solitary pulmonary nodule -- systematic review; Evidence-based medicine -- Periodicals; Systematic reviews (Medical research) -- Periodicals; 616.005
• DOI: 10.1111/jebm.12481
• Languages: English
• ISSNs: 1756-5383

Abstract

Abstract: Objective: To assess the association between prespecified factors and the malignancy risk of solitary pulmonary nodules (SPNs) to support the development of rapid recommendations for daily use in the Chinese setting. Methods: The expert panel for the rapid recommendations voted for 12 candidate factors based on published guidelines, selected publications, and clinical experiences. We then searched Medline, Embase, and Web of Science up to October 17, 2021, for studies investigating the association between these factors and the diagnosis of malignant SPNs in patients with CT‐identified SPNs through multivariable regression analysis. The risk of bias was assessed using the Agency for Healthcare Research and Quality (AHRQ) Checklist. We pooled adjusted odds ratios (aOR) between candidate factors and the diagnosis of the malignant SPNs. Results: A total of 32 cross‐sectional studies were included. Nine factors were statistically associated with malignant SPNs: age (aOR 1.06, 95% confidence interval [CI]: 1.05–1.07), smoking history (2.83, 1.84–4.36), history of extrathoracic malignancy (5.66, 2.80–11.46), history of malignancy (4.64, 3.37–6.39), family history of malignancy (3.11, 1.66–5.83), nodule diameter (1.23, 1.17–1.31), spiculation (3.41, 2.64–4.41), lobulation (3.85, 2.47–6.01), and mixed ground‐glass opacity (mGGO) density of the nodule (5.56, 2.47–12.52). No statistical association was found between family history of lung cancer, emphysema, nodule border, and malignant SPNs. Conclusion: Nine prespecified factors were associated with the concurrent malignancy risk among patients with SPNs. Risk stratification for SPNs is warranted in clinical practice.